Because randomization was not stratified for PD-L1 status, the imbalanced distribution of patients with PD-L1 highly positive NSCLC between study arms (Table 1) may have skewed deep pathological response rates in favor of nivolumab monotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.